Related Experiment Videos
TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy
1Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Abstract:
The tumour suppressor gene product TP53 is clearly a component in several biochemical pathways, including transcription, DNA repair, genomic stability, cell cycle control and apoptosis, that are central to human carcinogenesis. TP53 is functionally inactivated by mutational, viral and cellular mechanisms in the majority of human cancers. Analysis of the spectrum of TP53 mutations provides clues to the aetiology and molecular pathogenesis of cancer. Recent insight into the TP53 mediated biochemical pathways of cell cycle arrest and apoptosis has provided further understanding of the mechanisms related to TP53 mediated tumour suppression. This in turn may provide the potential molecular targets for the development of rational multimodality cancer therapy, including chemotherapy, immunotherapy and gene therapy strategies. The convergence of previously parallel lines of basic, clinical and epidemiological investigation may provide an opportunity for the rapid transfer of research findings from the laboratory to the clinic.
Insights
The tumor suppressor gene TP53 is crucial in preventing cancer by regulating cell cycles and apoptosis. Its inactivation is common in cancers, offering targets for new therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The TP53 gene product is a key tumor suppressor involved in critical cellular processes like DNA repair and apoptosis.
- Functional inactivation of TP53 occurs in most human cancers through various mechanisms.
- Understanding TP53's role is central to comprehending human carcinogenesis.
Purpose of the Study:
- To explore the role of TP53 in cancer development and its inactivation mechanisms.
- To investigate how TP53-mediated pathways inform cancer etiology and pathogenesis.
- To identify potential molecular targets for novel cancer therapies based on TP53 function.
Main Methods:
- Analysis of the spectrum of TP53 mutations in human cancers.
- Investigation of TP53-mediated biochemical pathways, including cell cycle arrest and apoptosis.
- Review of basic, clinical, and epidemiological data related to TP53.
Main Results:
- TP53 inactivation is a common event in human cancers.
- TP53 mutation analysis offers insights into cancer causes and development.
- Understanding TP53's role in cell cycle arrest and apoptosis enhances knowledge of tumor suppression.
Conclusions:
- TP53 is a critical tumor suppressor whose inactivation drives carcinogenesis.
- TP53 pathways present potential targets for innovative cancer treatments like chemotherapy, immunotherapy, and gene therapy.
- Integrating diverse research lines can accelerate the translation of TP53-related findings to clinical practice.